Loading
Life sciences · Journal article
Angewandte Chemie International Edition · October 10, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Phototheranostic agents operating in the second near-infrared (NIR-II) window hold great potential for precision cancer therapy, yet the rational regulation of excited-state processes to simultaneously optimize fluorescence and phototherapeutic performances remains a fundamental challenge. Herein, we report a topology-driven excited-state engineering strategy for constructing conjugated oligomers with tailored excited-state manifolds and multi-channel excitation dynamics. By precisely manipulating molecular topology, conjugated topological oligomers achieve enhanced light-harvesting capability and optimized exciton utilization, thereby enabling synergistic regulation of excitation dynamics. Under 808 nm laser irradiation, nanoparticles (NPs) derived from TBT-3 exhibit 2.8-fold enhanced NIR-II fluorescence brightness, 2.7-fold improved photothermal performance, and 7.5-fold increased total reactive oxygen species (ROS) generation compared with TBT-1. In vivo studies demonstrate that TBT-3 NPs enable high-resolution NIR-II fluorescence imaging and efficient tumor elimination. Moreover, TBT-3-mediated phototherapy induces immunogenic cell death and enhances antitumor immunity, leading to improved therapeutic efficacy when combined with anti-PD-1 immune checkpoint blockade. This work provides a molecular topology-based strategy for manipulating excited-state landscapes and establishes conjugated oligomers as versatile candidates for NIR-II phototheranostics and cancer immunotherapy.